img

Global mRNA Vaccines for Infectious Diseases Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global mRNA Vaccines for Infectious Diseases Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global mRNA Vaccines for Infectious Diseases market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Infectious Disease Vaccines accounting for % of the mRNA Vaccines for Infectious Diseases global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Infectious Disease segment is altered to an % CAGR throughout this forecast period.
The global key companies of mRNA Vaccines for Infectious Diseases include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
The United States mRNA Vaccines for Infectious Diseases market size was US$ million in 2024, while China size was US$ million. The proportion of the United States was % in 2024, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe mRNA Vaccines for Infectious Diseases landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global mRNA Vaccines for Infectious Diseases market. The analysts authoring the report have closely studied key strategies adopted by top players of the global mRNA Vaccines for Infectious Diseases market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global mRNA Vaccines for Infectious Diseases market. Readers of the report can become informed about current and future trends of the global mRNA Vaccines for Infectious Diseases market and how they will impact market growth during the forecast period.



By Company


Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Infectious Disease Vaccines
Cancer Vaccines

Segment by Application


Infectious Disease
Cancer
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of mRNA Vaccines for Infectious Diseases in global and regional level.
Chapter 3Detailed analysis of mRNA Vaccines for Infectious Diseases companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccines for Infectious Diseases revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Infectious Disease Vaccines
1.2.3 Cancer Vaccines
1.3 Market by Application
1.3.1 Global mRNA Vaccines for Infectious Diseases Market Growth Rate by Application: 2018 VS 2024 VS 2034
1.3.2 Infectious Disease
1.3.3 Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global mRNA Vaccines for Infectious Diseases Market Size (2018-2034)
2.2 mRNA Vaccines for Infectious Diseases Market Size across Key Geographies Worldwide: 2018 VS 2024 VS 2034
2.3 Global mRNA Vaccines for Infectious Diseases Market Size by Region (2018-2023)
2.4 Global mRNA Vaccines for Infectious Diseases Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 mRNA Vaccines for Infectious Diseases Countries Ranking by Market Size
3 mRNA Vaccines for Infectious Diseases Competitive by Company
3.1 Global mRNA Vaccines for Infectious Diseases Revenue by Players
3.1.1 Global mRNA Vaccines for Infectious Diseases Revenue by Players (2018-2023)
3.1.2 Global mRNA Vaccines for Infectious Diseases Market Share by Players (2018-2023)
3.2 Global mRNA Vaccines for Infectious Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by mRNA Vaccines for Infectious Diseases Revenue
3.4 Global mRNA Vaccines for Infectious Diseases Market Concentration Ratio
3.4.1 Global mRNA Vaccines for Infectious Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by mRNA Vaccines for Infectious Diseases Revenue in 2024
3.5 Global Key Players of mRNA Vaccines for Infectious Diseases Head office and Area Served
3.6 Global Key Players of mRNA Vaccines for Infectious Diseases, Product and Application
3.7 Global Key Players of mRNA Vaccines for Infectious Diseases, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global mRNA Vaccines for Infectious Diseases Breakdown Data by Type
4.1 Global mRNA Vaccines for Infectious Diseases Historic Revenue by Type (2018-2023)
4.2 Global mRNA Vaccines for Infectious Diseases Forecasted Revenue by Type (2024-2034)
5 Global mRNA Vaccines for Infectious Diseases Breakdown Data by Application
5.1 Global mRNA Vaccines for Infectious Diseases Historic Market Size by Application (2018-2023)
5.2 Global mRNA Vaccines for Infectious Diseases Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023)
6.2 North America mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2034)
6.3 North America mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2034)
6.4 North America mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023)
7.2 Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2034)
7.3 Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2034)
7.4 Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023)
8.2 Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2034)
8.3 Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2034)
8.4 Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023)
9.2 Latin America mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2034)
9.3 Latin America mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2034)
9.4 Latin America mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023)
10.2 Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2034)
10.3 Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2034)
10.4 Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Moderna Therapeutics
11.1.1 Moderna Therapeutics Company Details
11.1.2 Moderna Therapeutics Business Overview
11.1.3 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Products and Services
11.1.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.1.5 Moderna Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
11.1.6 Moderna Therapeutics Recent Development
11.2 CureVac
11.2.1 CureVac Company Details
11.2.2 CureVac Business Overview
11.2.3 CureVac mRNA Vaccines for Infectious Diseases Products and Services
11.2.4 CureVac mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.2.5 CureVac mRNA Vaccines for Infectious Diseases SWOT Analysis
11.2.6 CureVac Recent Development
11.3 Translate Bio
11.3.1 Translate Bio Company Details
11.3.2 Translate Bio Business Overview
11.3.3 Translate Bio mRNA Vaccines for Infectious Diseases Products and Services
11.3.4 Translate Bio mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.3.5 Translate Bio mRNA Vaccines for Infectious Diseases SWOT Analysis
11.3.6 Translate Bio Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Details
11.4.2 BioNTech Business Overview
11.4.3 BioNTech mRNA Vaccines for Infectious Diseases Products and Services
11.4.4 BioNTech mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.4.5 BioNTech mRNA Vaccines for Infectious Diseases SWOT Analysis
11.4.6 BioNTech Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Details
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Products and Services
11.5.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.5.5 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
11.5.6 Sangamo Therapeutics Recent Development
11.6 Argos Therapeutics
11.6.1 Argos Therapeutics Company Details
11.6.2 Argos Therapeutics Business Overview
11.6.3 Argos Therapeutics mRNA Vaccines for Infectious Diseases Products and Services
11.6.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.6.5 Argos Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
11.6.6 Argos Therapeutics Recent Development
11.7 In-Cell-Art
11.7.1 In-Cell-Art Company Details
11.7.2 In-Cell-Art Business Overview
11.7.3 In-Cell-Art mRNA Vaccines for Infectious Diseases Products and Services
11.7.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.7.5 In-Cell-Art mRNA Vaccines for Infectious Diseases SWOT Analysis
11.7.6 In-Cell-Art Recent Development
11.8 eTheRNA
11.8.1 eTheRNA Company Details
11.8.2 eTheRNA Business Overview
11.8.3 eTheRNA mRNA Vaccines for Infectious Diseases Products and Services
11.8.4 eTheRNA mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.8.5 eTheRNA mRNA Vaccines for Infectious Diseases SWOT Analysis
11.8.6 eTheRNA Recent Development
11.9 Ethris
11.9.1 Ethris Company Details
11.9.2 Ethris Business Overview
11.9.3 Ethris mRNA Vaccines for Infectious Diseases Products and Services
11.9.4 Ethris mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.9.5 Ethris mRNA Vaccines for Infectious Diseases SWOT Analysis
11.9.6 Ethris Recent Development
11.10 Tiba Biotechnology
11.10.1 Tiba Biotechnology Company Details
11.10.2 Tiba Biotechnology Business Overview
11.10.3 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Products and Services
11.10.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023)
11.10.5 Tiba Biotechnology mRNA Vaccines for Infectious Diseases SWOT Analysis
11.10.6 Tiba Biotechnology Recent Development
12 mRNA Vaccines for Infectious Diseases Market Dynamics
12.1 mRNA Vaccines for Infectious Diseases Industry Trends
12.2 mRNA Vaccines for Infectious Diseases Market Drivers
12.3 mRNA Vaccines for Infectious Diseases Market Challenges
12.4 mRNA Vaccines for Infectious Diseases Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2024 VS 2034
Table 2. Key Players of Infectious Disease Vaccines
Table 3. Key Players of Cancer Vaccines
Table 4. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Application (US$ Million), 2018 VS 2024 VS 2034
Table 5. Global mRNA Vaccines for Infectious Diseases Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2024 VS 2034
Table 6. Global mRNA Vaccines for Infectious Diseases Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global mRNA Vaccines for Infectious Diseases Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global mRNA Vaccines for Infectious Diseases Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Table 9. Global mRNA Vaccines for Infectious Diseases Revenue by Players (2018-2023) & (US$ Million)
Table 10. Global mRNA Vaccines for Infectious Diseases Market Share by Players (2018-2023)
Table 11. Global Top mRNA Vaccines for Infectious Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Infectious Diseases as of 2024)
Table 12. Ranking of Global Top mRNA Vaccines for Infectious Diseases Companies by Revenue (US$ Million) in 2024
Table 13. Global 5 Largest Players Market Share by mRNA Vaccines for Infectious Diseases Revenue (CR5 and HHI) & (2018-2023)
Table 14. Global Key Players of mRNA Vaccines for Infectious Diseases, Headquarters and Area Served
Table 15. Global Key Players of mRNA Vaccines for Infectious Diseases, Product and Application
Table 16. Global Key Players of mRNA Vaccines for Infectious Diseases, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global mRNA Vaccines for Infectious Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 19. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2023)
Table 20. Global mRNA Vaccines for Infectious Diseases Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2024-2034)
Table 22. Global mRNA Vaccines for Infectious Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2023)
Table 24. Global mRNA Vaccines for Infectious Diseases Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2024-2034)
Table 26. North America mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023) & (US$ Million)
Table 27. North America mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 28. North America mRNA Vaccines for Infectious Diseases Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 30. North America mRNA Vaccines for Infectious Diseases Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America mRNA Vaccines for Infectious Diseases Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 32. North America mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2023) & (US$ Million)
Table 33. North America mRNA Vaccines for Infectious Diseases Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023) & (US$ Million)
Table 35. Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 36. Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 38. Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe mRNA Vaccines for Infectious Diseases Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 40. Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2023) & (US$ Million)
Table 41. Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023) & (US$ Million)
Table 43. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 44. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 46. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific mRNA Vaccines for Infectious Diseases Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 48. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Region (2018-2023) & (US$ Million)
Table 49. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023) & (US$ Million)
Table 51. Latin America mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 52. Latin America mRNA Vaccines for Infectious Diseases Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 54. Latin America mRNA Vaccines for Infectious Diseases Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America mRNA Vaccines for Infectious Diseases Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 56. Latin America mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2023) & (US$ Million)
Table 57. Latin America mRNA Vaccines for Infectious Diseases Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2023) & (US$ Million)
Table 59. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 60. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 62. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 64. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Country (2018-2023) & (US$ Million)
Table 65. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue by Country (2024-2034) & (US$ Million)
Table 66. Moderna Therapeutics Company Details
Table 67. Moderna Therapeutics Business Overview
Table 68. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product and Services
Table 69. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 70. Moderna Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 71. Moderna Therapeutics Recent Development
Table 72. CureVac Company Details
Table 73. CureVac Business Overview
Table 74. CureVac mRNA Vaccines for Infectious Diseases Product and Services
Table 75. CureVac mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 76. CureVac mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 77. CureVac Recent Development
Table 78. Translate Bio Company Details
Table 79. Translate Bio Business Overview
Table 80. Translate Bio mRNA Vaccines for Infectious Diseases Product and Services
Table 81. Translate Bio mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 82. Translate Bio mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 83. Translate Bio Recent Development
Table 84. BioNTech Company Details
Table 85. BioNTech Business Overview
Table 86. BioNTech mRNA Vaccines for Infectious Diseases Product and Services
Table 87. BioNTech mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 88. BioNTech mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 89. BioNTech Recent Development
Table 90. Sangamo Therapeutics Company Details
Table 91. Sangamo Therapeutics Business Overview
Table 92. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product and Services
Table 93. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 94. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 95. Sangamo Therapeutics Recent Development
Table 96. Argos Therapeutics Company Details
Table 97. Argos Therapeutics Business Overview
Table 98. Argos Therapeutics mRNA Vaccines for Infectious Diseases Product and Services
Table 99. Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 100. Argos Therapeutics mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 101. Argos Therapeutics Recent Development
Table 102. In-Cell-Art Company Details
Table 103. In-Cell-Art Business Overview
Table 104. In-Cell-Art mRNA Vaccines for Infectious Diseases Product and Services
Table 105. In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 106. In-Cell-Art mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 107. In-Cell-Art Recent Development
Table 108. eTheRNA Company Details
Table 109. eTheRNA Business Overview
Table 110. eTheRNA mRNA Vaccines for Infectious Diseases Product and Services
Table 111. eTheRNA mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 112. eTheRNA mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 113. eTheRNA Recent Development
Table 114. Ethris Company Details
Table 115. Ethris Business Overview
Table 116. Ethris mRNA Vaccines for Infectious Diseases Product and Services
Table 117. Ethris mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 118. Ethris mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 119. Ethris Recent Development
Table 120. Tiba Biotechnology Company Details
Table 121. Tiba Biotechnology Business Overview
Table 122. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product and Services
Table 123. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue in mRNA Vaccines for Infectious Diseases Business (2018-2023) & (US$ Million)
Table 124. Tiba Biotechnology mRNA Vaccines for Infectious Diseases SWOT Analysis
Table 125. Tiba Biotechnology Recent Development
Table 126. mRNA Vaccines for Infectious Diseases Market Trends
Table 127. mRNA Vaccines for Infectious Diseases Market Drivers
Table 128. mRNA Vaccines for Infectious Diseases Market Challenges
Table 129. mRNA Vaccines for Infectious Diseases Market Restraints
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. mRNA Vaccines for Infectious Diseases Product Picture
Figure 2. Global mRNA Vaccines for Infectious Diseases Market Size by Type (US$ Million): 2018 VS 2024 VS 2034
Figure 3. Global mRNA Vaccines for Infectious Diseases Market Share by Type: 2024 VS 2034
Figure 4. Infectious Disease Vaccines Features
Figure 5. Cancer Vaccines Features
Figure 6. Global mRNA Vaccines for Infectious Diseases Market Size by Application (US$ Million): 2018 VS 2024 VS 2034
Figure 7. Global mRNA Vaccines for Infectious Diseases Market Share by Application: 2024 VS 2034
Figure 8. Infectious Disease
Figure 9. Cancer
Figure 10. mRNA Vaccines for Infectious Diseases Report Years Considered
Figure 11. Global mRNA Vaccines for Infectious Diseases Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 12. Global mRNA Vaccines for Infectious Diseases Market Size 2018-2034 (US$ Million)
Figure 13. Global mRNA Vaccines for Infectious Diseases Market Size Market Share by Region: 2024 VS 2034
Figure 14. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Region in 2018 VS 2024
Figure 15. Global mRNA Vaccines for Infectious Diseases Revenue Market Share Forecast by Region (2024-2034)
Figure 16. Global Top 10 mRNA Vaccines for Infectious Diseases Countries Ranking by Market Size (US$ Million) in 2024
Figure 17. Global mRNA Vaccines for Infectious Diseases Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Figure 18. Global mRNA Vaccines for Infectious Diseases Market Share by Players in 2024
Figure 19. Global Top mRNA Vaccines for Infectious Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Infectious Diseases as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by mRNA Vaccines for Infectious Diseases Revenue in 2024
Figure 21. North America mRNA Vaccines for Infectious Diseases Revenue Market Share by Company in 2024
Figure 22. North America mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2034)
Figure 23. North America mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2034)
Figure 24. North America mRNA Vaccines for Infectious Diseases Revenue Share by Country (2018-2034)
Figure 25. United States mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 26. Canada mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 27. Europe mRNA Vaccines for Infectious Diseases Revenue Market Share by Company in 2024
Figure 28. Europe mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2034)
Figure 29. Europe mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2034)
Figure 30. Europe mRNA Vaccines for Infectious Diseases Revenue Share by Country (2018-2034)
Figure 31. Germany mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 32. France mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 33. U.K. mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 34. Italy mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 35. Russia mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 36. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue Market Share by Company in 2024
Figure 37. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2034)
Figure 38. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2034)
Figure 39. Asia Pacific mRNA Vaccines for Infectious Diseases Revenue Share by Region (2018-2034)
Figure 40. China mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 41. Japan mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 42. South Korea mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 43. India mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 44. Australia mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 45. China Taiwan mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 46. Indonesia mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 47. Thailand mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 48. Malaysia mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 49. Latin America mRNA Vaccines for Infectious Diseases Revenue Market Share by Company in 2024
Figure 50. Latin America mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2034)
Figure 51. Latin America mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2034)
Figure 52. Latin America mRNA Vaccines for Infectious Diseases Revenue Share by Country (2018-2034)
Figure 53. Mexico mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 54. Brazil mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 55. Argentina mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 56. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue Market Share by Company in 2024
Figure 57. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2018-2034)
Figure 58. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2018-2034)
Figure 59. Middle East and Africa mRNA Vaccines for Infectious Diseases Revenue Share by Country (2018-2034)
Figure 60. Turkey mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 61. Saudi Arabia mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 62. UAE mRNA Vaccines for Infectious Diseases Revenue (2018-2034) & (US$ Million)
Figure 63. Moderna Therapeutics Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 64. CureVac Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 65. Translate Bio Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 66. BioNTech Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 67. Sangamo Therapeutics Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 68. Argos Therapeutics Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 69. In-Cell-Art Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 70. eTheRNA Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 71. Ethris Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 72. Tiba Biotechnology Revenue Growth Rate in mRNA Vaccines for Infectious Diseases Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed